Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma

NCT03282396 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Mantle Cell Lymphoma

Interventions

DRUG: Ibrutinib

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]